First gene therapy for a blinding eye disease receives FDA approval
Today we are celebrating the FDA’s pathbreaking approval of Luxturna. We have been following the development of Luxturna closely. Today’s landmark FDA approval makes Luxturna the first gene therapy approved in the…
Research News
July 2024 First patients treated in XLRP gene therapy trial Beacon Therapeutics, has announced that they have treated the first patients in their Phase 2/3 VISTA trial for a gene therapy for…
New Survey Initiative Engages Patients as Experts and Collaborators
Last year Fighting Blindness Canada launched its Vision Care Pathways (VCP) online tool, a set of resources and guides for people living with eye diseases. These diseases include rare genetic disorders such…
The Era of Gene Therapy – A Panel Discussion
In this panel discussion from Vision Quest Vancouver on April 27, 2019, experts from around the world introduced the new era of gene therapy and discussed what this means for the future…
X-Linked Retinoschisis
Jump to: Symptoms | Diagnosis | Treatments | Clinical Trials | Patient Registry | Research | Resources | References Overview X-linked retinoschisis (XLRS) is a genetic disorder that causes vision loss and…
Usher Syndrome
Jump to: Symptoms | Diagnosis | Treatment | Clinical Trials | Patient Registry | Research | Resources | References Overview Usher syndrome is a genetic disorder characterized by the loss of both…
Join the Fight!
Learn how your support is helping to bring a future without blindness into focus! Be the first to learn about the latest breakthroughs in vision research and events in your community by subscribing to our e-newsletter that lands in inboxes the beginning of each month.
